EP1276755A4 - Neue verbindungen - Google Patents

Neue verbindungen

Info

Publication number
EP1276755A4
EP1276755A4 EP01930760A EP01930760A EP1276755A4 EP 1276755 A4 EP1276755 A4 EP 1276755A4 EP 01930760 A EP01930760 A EP 01930760A EP 01930760 A EP01930760 A EP 01930760A EP 1276755 A4 EP1276755 A4 EP 1276755A4
Authority
EP
European Patent Office
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01930760A
Other languages
English (en)
French (fr)
Other versions
EP1276755A1 (de
Inventor
Pankaj Agarwal
Paul R Murdock
Safia K Rizvi
Randall F Smith
Zhaoying Xiang
Karen S Kabnick
Ying-Ta Lai
Qing Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of EP1276755A1 publication Critical patent/EP1276755A1/de
Publication of EP1276755A4 publication Critical patent/EP1276755A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
EP01930760A 2000-04-27 2001-04-26 Neue verbindungen Withdrawn EP1276755A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US19996300P 2000-04-27 2000-04-27
US199963P 2000-04-27
US20333600P 2000-05-11 2000-05-11
US203336P 2000-05-11
US20708700P 2000-05-25 2000-05-25
US207087P 2000-05-25
US20754600P 2000-05-26 2000-05-26
US207546P 2000-05-26
PCT/US2001/013360 WO2001081363A1 (en) 2000-04-27 2001-04-26 Novel compounds

Publications (2)

Publication Number Publication Date
EP1276755A1 EP1276755A1 (de) 2003-01-22
EP1276755A4 true EP1276755A4 (de) 2004-03-31

Family

ID=27498358

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01930760A Withdrawn EP1276755A4 (de) 2000-04-27 2001-04-26 Neue verbindungen

Country Status (15)

Country Link
EP (1) EP1276755A4 (de)
JP (1) JP2003530869A (de)
KR (1) KR20030032940A (de)
CN (1) CN1439017A (de)
AU (1) AU2001257265A1 (de)
BR (1) BR0110402A (de)
CA (1) CA2407449A1 (de)
CZ (1) CZ20023548A3 (de)
HK (1) HK1053840A1 (de)
HU (1) HUP0300595A3 (de)
IL (1) IL152416A0 (de)
MX (1) MXPA02010692A (de)
NO (1) NO20025151L (de)
PL (1) PL358580A1 (de)
WO (1) WO2001081363A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558936B1 (en) * 1999-10-01 2003-05-06 Millennium Pharmaceuticals, Inc. Human lipase proteins, nucleic acids encoding them, and uses of both of these
US6630335B1 (en) 2000-02-11 2003-10-07 Millennium Pharmaceuticals, Inc. 14171 protein kinase, a novel human protein kinase and uses thereof
NZ523122A (en) * 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
WO2002002772A2 (en) * 2000-06-30 2002-01-10 Incyte Genomics, Inc. Human extracellular matrix (ecm)-related tumor marker
US6924364B2 (en) 2000-08-04 2005-08-02 Zymogenetics, Inc. Human secreted protein, Zzp1
ATE353366T1 (de) 2000-08-22 2007-02-15 Agensys Inc Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU1181802A (en) 2000-09-27 2002-04-08 Curagen Corp Novel proteins and nucleic acids encoding same
WO2002026826A2 (en) * 2000-09-27 2002-04-04 Curagen Corporation Proteins and nucleic acids encoding same
CA2430257A1 (en) * 2000-11-28 2002-06-06 Amgen, Inc. Transforming growth factor-beta-related molecules and uses thereof
WO2002072769A2 (en) * 2001-03-08 2002-09-19 Immunex Corporation Human serpin polypeptides
US6921807B2 (en) 2001-03-29 2005-07-26 Zymogenetics, Inc. Proteinase inhibitor ZSERP9
US20020172995A1 (en) * 2001-05-17 2002-11-21 Wei Shao Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
AU2002318513A1 (en) * 2001-07-06 2003-01-21 Nsgene A/S Novel neurotrophic factors
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
JP2007524361A (ja) * 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
JP4429269B2 (ja) 2003-02-10 2010-03-10 大正製薬株式会社 アポトーシス誘導遺伝子およびその利用
US20050048615A1 (en) * 2003-08-01 2005-03-03 Fox Brian A. Adipocyte complement related protein zacrp11
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
EP3494996A1 (de) 2012-08-23 2019-06-12 Agensys, Inc. An 158p1d7-proteine bindende antikörperwirkstoffkonjugate
CA3009127A1 (en) * 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1995030428A1 (en) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Human dnase
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
HUP0300595A3 (en) 2007-06-28
EP1276755A1 (de) 2003-01-22
HK1053840A1 (zh) 2003-11-07
BR0110402A (pt) 2003-02-11
MXPA02010692A (es) 2003-03-10
NO20025151D0 (no) 2002-10-25
CN1439017A (zh) 2003-08-27
AU2001257265A1 (en) 2001-11-07
WO2001081363A1 (en) 2001-11-01
CZ20023548A3 (cs) 2003-05-14
NO20025151L (no) 2002-12-13
HUP0300595A2 (hu) 2003-06-28
JP2003530869A (ja) 2003-10-21
IL152416A0 (en) 2003-05-29
PL358580A1 (en) 2004-08-09
KR20030032940A (ko) 2003-04-26
CA2407449A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
EP1276755A4 (de) Neue verbindungen
AU9261901A (en) Novel compounds
GB0003019D0 (en) Novel compounds
EP1255771A4 (de) Neue zusammensetzungen
GB0008464D0 (en) Novel compounds
EP1292617A4 (de) Neuartige Verbindungen
EP1472352A4 (de) Neue verbindungen
EP1343813A4 (de) Neue verbindungen
AU7476401A (en) Novel compounds
EP1276866A4 (de) Neue verbindungen
GB0004149D0 (en) Novel compounds
EP1299530A4 (de) Neuartige verbindungen
GB0001898D0 (en) Novel compounds
GB0003636D0 (en) Novel compounds
GB0002402D0 (en) Novel compounds
GB0004196D0 (en) Novel compounds
EG22332A (en) Novel compounds
GB0000928D0 (en) Novel compounds
GB0004269D0 (en) Novel compounds
GB0002330D0 (en) Novel compounds
GB0002401D0 (en) Novel compounds
GB0002195D0 (en) Novel compounds
GB0002191D0 (en) Novel compounds
GB0003023D0 (en) Novel compounds
GB0003103D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20021024

A4 Supplementary search report drawn up and despatched

Effective date: 20040212

17Q First examination report despatched

Effective date: 20040811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1053840

Country of ref document: HK